Claire Xu, MD, PhD, joined I-Mab in January 2018 as the U.S. site head, leading the establishment of I-Mab’s Maryland site and the continual growth of I-Mab’s U.S. clinical team. Dr. Xu oversees the U.S. medical/clinical research, clinical operation, regulatory affairs, clinical biomarkers and project management for I-Mab’s global portfolios. Her team also collaborates closely with I-Mab’s teams in China on global development strategy and execution.
Prior to joining I-Mab, Dr. Xu was the associate director of clinical pharmacology at Otsuka Pharmaceutical Development & Commercialization, where she was responsible for designing and overseeing multiple phase 1/2 studies of different therapeutic areas, including hematology/oncology. Dr. Xu received her PhD in clinical pharmacology from Indiana University School of Medicine and her Bachelor of Medicine degree from Zhongshan School of Medicine, Sun Yat-sen University, China.